Comparison of Routine Versus Restrictive Episiotomy in Primigravida Women at Term.
Comparison of Outcome in Terms of Perineal Tear and Postpartum Hemorrhage (PPH) in Routine Versus Restrictive Episiotomy in Primigravida Women at Term.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Punjab Province
-
Multan, Punjab Province, Pakistan, 66000
- Nishtar Hospital/Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Primigravida
- Aged18 - 40 years
- Gestational age of ≥ 37 weeks
- Admitted to the labor room (either spontaneous or induced labor) for episiotomy
Exclusion Criteria:
- Abnormal and cephalic presentations with occipitoposterior position
- Instrumental delivery (vacuum or forceps)
- Pre - eclampsia / Eclampsia
- Gestational diabetes mellitus
- Fetal abnormality
- Intrauterine growth restriction
- History of pelvic surgery or neuromuscular diseases
- Twin pregnancies
- Fetal macrosomia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Routine Episiotomy
Patients were managed by routine method in which episiotomy was performed without any indication.
|
Patients were managed by routine method in which episiotomy was performed without any indication.
|
|
Experimental: Restrictive Episiotomy
The patient underwent restrictive episiotomy when clinically indicated due to a risk of a third- or fourth-degree perineal tear or fetal compromise.
|
The patient underwent restrictive episiotomy when clinically indicated due to a risk of a third- or fourth-degree perineal tear or fetal compromise.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perineal tear
Time Frame: Immediately after the procedure
|
Frequency of patients with perineal tear, defined as presence of laceration or disruption at any level from skin to the muscles and anal sphincters, was noted, .
|
Immediately after the procedure
|
|
Postpartum Hemorrhage
Time Frame: Immediately after the procedure
|
Frequency of patients with postpartum hemorrhage, defined as Blood loss of more than 500 mL after vaginal delivery measured as one full kidney tray, was noted.
|
Immediately after the procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ammara Khaliq, Nishtar Hospital/Medical University, Multan, Pakistan.
- Study Director: Syeda Ali, FCPS, Nishtar Hospital/Medical University, Multan, Pakistan.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Dr-Ammara-Multan
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.